

AD_____

Award Number: ~~DAMD~~17-03-1-0381

TITLE: Antiangiogenic Steroids and Growth Factor Receptors in
Human Breast Cancer Therapy

PRINCIPAL INVESTIGATOR: Richard J. Pietras, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of California, Los Angeles
Los Angeles, California 90024

REPORT DATE: August 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050415 231

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 2004		3. REPORT TYPE AND DATES COVERED Annual (1 Aug 2003 - 31 Jul 2004)
4. TITLE AND SUBTITLE Antiangiogenic Steroids and Growth Factor Receptors in Human Breast Cancer Therapy			5. FUNDING NUMBERS DAMD17-03-1-0381	
6. AUTHOR(S) Richard J. Pietras, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, Los Angeles Los Angeles, California 90024 E-Mail: rpietras@ucla.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) With 1,000,000 new cases worldwide annually, breast cancer is the most common malignancy in women. Genesis of these cancers depends, in part, on formation of a good blood supply, a process termed angiogenesis. Vascular endothelial growth factor (VEGF) stimulates growth of endothelial cells, and this critical protein is produced by breast cancers. High levels of VEGF secretion occur in tumors expressing EGF and HER-2 growth factor receptors. Antibodies to HER-2 receptor elicit direct antitumor effects but also reduce VEGF secretion from tumors and, thereby, decrease angiogenesis. Optimal suppression of tumor growth may be achieved by combining anti-growth factor receptor therapies with agents that disrupt tumor angiogenesis, such as squalamine, a steroid that blocks VEGF-induced activity. This study probes the notion that treating both the tumor and the tumor-associated vasculature may be more effective than treating cancer cells alone. We are assessing specific binding and biologic activities of squalamine using vascular endothelial cells, with evidence for localization of squalamine in caveolae signaling domains. Moreover, we are evaluating the efficacy of squalamine alone and combined with other biologic agents, such as Herceptin and 2C4, in blocking growth and progression of human breast cancer xenografts in vivo.				
14. SUBJECT TERMS Breast cancer, angiogenesis, squalamine, HER-2/neu receptor, VEGF			15. NUMBER OF PAGES 11	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Conclusions.....	8
References.....	9
Appendices.....	none

INTRODUCTION

With 1,000,000 new cases in the world annually, breast cancer is the most common malignancy in women (1). Recent advances in surgery, radiation and chemotherapy have improved overall survival, but improved treatment options for patients afflicted with breast cancer are urgently needed. Although the cause of most breast cancers is unknown, epidermal growth factor receptor (EGFR) family members, HER-2 and EGFR, are often implicated in the pathogenesis of this cancer (2,3). HER-2 receptors are overexpressed in 25-30% of newly diagnosed breast cancers, and HER-2 amplification correlates with poor clinical course (4-7). Moreover, antibodies specific for HER-2 receptor (8-10) elicit *in vivo* a marked cytostatic growth inhibition of breast cancers that overexpress the HER-2 gene product (see Fig. 1).




FIG. 1. Breast tumor-associated angiogenesis. Cancers with HER-2 and/or EGF receptors secrete endothelial growth factors. VEGF binds its receptor (11) and growth factor regulation of vessel growth converges with signaling by MAP kinases (12,13). Squalamine, possibly by binding surface proton pumps (14,15) or unknown membrane sites, may disrupt MAPK signaling in endothelial cells to block growth. Receptor tyrosine kinase inhibitor (RTKi); HER-2 monoclonal antibody (MAb); epidermal growth factor receptor (EGFR).

Growth of breast cancer depends, in part, on formation of an adequate blood supply. Tumor angiogenesis has prognostic significance in breast cancer (16), and vascular endothelial growth factor (VEGF) may play a critical role in breast cancer progression (17). HER-2 and EGF receptor signaling is reported to up-regulate secretion of VEGF in solid tumors (18), including breast cancer (18,19), and treatments targeted to block VEGF or other angiogenic molecules may stop tumor progression (20). Therapy directed toward the vasculature of solid tumors is now being pursued as an important new direction in cancer treatment, because avascular tumors exhibit limited growth (4,5) and tumor aggressiveness and metastatic potential commonly correlate with tumor vascularity (6).

Squalamine, a natural steroidal molecule, has antiangiogenic activity in models of breast, ovary, brain and lung cancer (21-23). Angiostatic steroids were first described 20 years ago (20,24), but squalamine, a 7,24 dihydroxylated 24-sulfated cholestane steroid conjugated to a spermidine at C-3 (25,26), differs in structure from the earlier agents. Squalamine is unique among most angiostatic agents currently in development because it blocks endothelial growth induced by a wide range of growth factors including bFGF and VEGF (15,26). This inhibition may result from interaction with endothelial cell surface proton pumps, thus altering intracellular pH and impeding growth factor signaling (15,25,26), or with other membrane signaling components (23). In vascular endothelial cells, squalamine blocks growth factor-induced activation of MAP kinase signaling, an enzyme at a crucial point of convergence for several growth factor signaling cascades (23). Administered as a single agent, squalamine is relatively non-toxic and well tolerated in early clinical trials (27-29).

BODY: RESEARCH PROGRESS

AIM 1. *Assessment of the specific binding, subcellular distribution and biologic activities of squalamine, a newly-synthesized antiangiogenic steroid, using human vascular endothelial cells in vitro.*

1.1. Squalamine blocks endothelial growth factor-stimulated proliferation of endothelial cells *in vitro*. To assess biologic mechanisms for antitumor effects of squalamine, human umbilical vein endothelial cells (HUVEC) were grown *in vitro*. VEGF is a critical endothelial growth factor secreted by breast cancers, and the peptide elicits growth of HUVEC cells by 72 h (Fig. 2). In the absence of VEGF, squalamine has no significant effect on proliferation of endothelial cells. However, squalamine elicits a marked reduction in VEGF-induced endothelial growth ($P < 0.001$). This growth-inhibitory effect of squalamine appears restricted to endothelial cells since it had no direct effect on growth of breast cells.




FIG. 2. Squalamine (SQ) disrupts vascular endothelial cell growth. Human vascular endothelial cells (HUVEC), MCF-7/PAR or MCF-7/HER2 cells were treated with control vehicle (CON), VEGF (20 ng/ml), squalamine (SQ; 16 μ M), Herceptin (Ab) or a combination of squalamine and Herceptin (SQ/Ab).

1.2. Squalamine does not affect VEGF secretion *in vitro* for breast cancer cells with or without HER-2 gene overexpression. HER-2 is thought to elicit tumor progression via its effects on promoting cancer cell growth, but recent data show that HER-2 may also regulate angiogenesis by promoting tumor VEGF production (18,19). To evaluate HER-2 effects on VEGF, MCF-7 parent and HER-2 cells were plated for 72 h *in vitro*, and secretion of VEGF into the media was determined by ELISA (11,23,29) (FIG. 3).




FIG. 3. HER-2 gene overexpression promotes enhanced secretion of VEGF in breast tumor cells *in vitro*. Parental MCF-7 cells (PAR) and HER2-overexpressing (HER-2) cells were incubated without (CON) or with squalamine (SQ), Herceptin (Ab) or squalamine-Herceptin (SQ/Ab) for 72 hr, with VEGF in extracellular media assayed by ELISA. Data given as mean \pm SEM. See text for details (23,29).

Parent cells exhibit significant secretion of VEGF, and, after HER-2 transfection, a further increase in VEGF secretion was found. In parallel studies, squalamine elicited no effect on VEGF secretion (FIG. 3). Thus, HER-2 may contribute to angiogenesis via up-regulation of VEGF secretion in breast cancer, but squalamine is not antiangiogenic at this step in angiogenesis since it does not appear to directly affect secretion of VEGF by breast tumor cells. However, as reported previously (23,32), Herceptin elicits a significant reduction in VEGF secretion in the presence or absence of squalamine ($P < 0.01$).

1.3. Squalamine blocks VEGF-induced activation of MAP kinases *in vitro*. VEGF exerts its effects by binding with receptor tyrosine kinases, Flt-1 and Flk-1/KDR, at endothelial cell surfaces (12,30). Post-receptor signaling regulates the proliferative action of VEGF that is associated, in turn, with tyrosine phosphorylation and stimulation of mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase ERK-1 (p44^{MAPK}) and ERK-2 (p42^{MAPK}) (12,31). We reported that blockade of endothelial cell growth by squalamine may occur, in part, by suppression of MAPK signaling induced by growth factors, such as VEGF. VEGF, given alone to vascular endothelial cells, promotes tyrosine phosphorylation of p42/p44 MAPK isoforms, but, after co-administration with squalamine, VEGF-induced phosphorylation of MAPK is significantly suppressed, thus suggesting inhibitory effects of squalamine (23,32). Thus, these and independent studies suggest that MAPK's may be a major point of convergence for many angiogenic cascades, and assay for MAPK activation may be a useful screen for effects of squalamine.

Importantly, the SAPK2/p38 MAP kinase pathway is a stress-activated kinase cascade that is also stimulated by VEGF in human vascular endothelial cells. To assess potential inhibitory effects of squalamine on this downstream signaling pathway, we conducted experiments to investigate VEGF-induced effects on p38 MAPK. To detect phosphorylated forms of p38 MAP Kinase, human vascular endothelial cells were plated on glass slides in complete media. When cells reached about 80% confluency, they were serum-starved for 16-18 h and washed twice with PBS before treatment. We then treated cells with control, 160 nM of squalamine control for 1 h, 50 ng/mL of VEGF for 10 min, or a combination of a pre-treatment with squalamine for 1 h followed by the addition of 50 ng/mL of VEGF the last 10 min. After treatment, cells were immediately rinsed with cold PBS and prepared for viewing by confocal microscopy, using antibodies against phospho-p38 MAP kinase

(Thr180/Tyr182)(Cell Signaling)(32). As expected, treatment of vascular endothelial cells with VEGF *in vitro* elicited significant phosphorylation of p38 MAP kinase by 10 min. However, after addition of squalamine, the VEGF-stimulated phosphorylation of p38 MAP kinase was significantly reduced and far less predominant. Squalamine-mediated changes in VEGF-induced activation of SAPK2/p38 MAP kinase may have mechanistic significance, since activated p38 MAP kinase is associated with F-actin formation and focal adhesion assembly, important functions in the migration and proliferation of vascular endothelial cells (30-34).

1.4. Squalamine suppresses VEGF-stimulated endothelial cell tube-like formation *in vitro* To assess the role of squalamine inhibition of VEGF signaling early in the process of angiogenesis, human vascular endothelial cells were plated on growth factor-depleted Matrigel (32,33). At doses as low as 160 nM, squalamine was found to block VEGF-induced capillary tube formation. However, VEGF-stimulated capillary tube formation was not significantly disrupted by 1.6 nM squalamine. The inhibitory effect of squalamine on capillary tube formation by endothelial cells appears to occur in a dose-dependent manner. Cells in plates in which networked capillary tubes were inhibited by squalamine displayed a profound alteration in shape and size (i.e., round and small) as compared with more characteristic spindle-shaped, elongate cells that form tubes in the absence of squalamine. These experiments are continuing in the current period.

1.5. Squalamine Interacts with Caveolae Signaling Domains of Human Vascular Endothelial Cells *in vitro*. To further assess potential biologic mechanisms for antiangiogenic and antitumor effects of squalamine noted above, human umbilical vein endothelial cells (HUVEC) were grown *in vitro*. We have hypothesized that antiangiogenic effects of squalamine may be due, in part, to binding of squalamine with caveolae localized in plasma membranes of human vascular cells. Caveolae are plasma membrane domains that act as signaling platforms to intercept a variety of agonists, both protein and lipid, in endothelial cells. To evaluate these membrane subfractions as a primary site of squalamine interaction with endothelial cells, we prepared caveolae membranes from HUVEC cells using a detergent-free method and measured specific binding of [3 H]-squalamine (Perkin Elmer-New England Nuclear) using established methods (35-37). An example of purification of a caveolae membrane fraction from human vascular endothelial cells is shown in Fig. 4. The endothelial cells exhibit enrichment of caveolin-1 in caveolae-related domains. In addition, we find localization of specific [3 H]-squalamine binding-sites in caveolin-enriched membrane fractions.




Fig. 4. Purification of caveolae membrane sub-fractions from human vascular endothelial cells. The cells show significant enrichment of caveolin-1 in


caveolae domains, gradient fractions 4-6, isolated from vascular endothelial cells by use of established detergent-free methods. In addition, specific binding of [3 H]-squalamine localizes to the same gradient fractions that contain caveolin (gradient fractions 4-6, see figure above). Specific binding of [3 H]-squalamine was assessed by use of established methods. Results of one representative experiment are shown.

The nature of squalamine binding with caveolae was investigated further in a set of equilibrium binding studies. Data obtained from these experiments indicate that *in vitro* binding of [3 H]-squalamine at concentrations ranging from 10-400 nM to caveolae membranes is saturable (data not shown). The squalamine-binding properties of the caveolae were analyzed further to obtain an estimate of both the concentration of specific binding sites for squalamine and the equilibrium constant. Preliminary analysis of the data by the method of Scatchard indicate that the dissociation constant (K_d) for the binding process is 7.5×10^{-8} M. Total binding sites for squalamine at saturation correspond to a maximal binding capacity (B_{max}) of 10 pmol/mg protein. The ligand specificity of [3 H]-squalamine binding to caveolae was analyzed by competitive binding of a 100-fold molar excess of unlabelled squalamine or other common steroidal compounds. The extent of [3 H]-squalamine binding by caveolae was largely unaffected by such excess of estradiol-17 β , progesterone, or cortisol. In contrast, unlabelled squalamine elicited nearly complete reduction of specific [3 H]-squalamine binding to caveolae

membranes. The data suggest that caveolae at the surface membrane of endothelial cells may offer a primary interaction site for squalamine.

AIM 2. *Investigation of the efficacy of squalamine alone and combined with other antitumor agents in blocking growth and progression of human breast cancer xenografts in nude mice.*

2.1. Squalamine and Herceptin block growth of breast tumors with HER-2 overexpression in vivo Antitumor activity of the antiangiogenic steroid, squalamine, was evaluated using human MCF-7 breast tumors with or without overexpression of HER-2. Tumors were grown as subcutaneous xenografts and treated with control, Herceptin, squalamine or squalamine in combination with Herceptin (Fig. 5).



Squalamine alone retards growth of MCF-7 cells with or without HER-2 overexpression ($P < 0.001$), while Herceptin alone blocks growth of MCF-7/HER-2 but not MCF-7/PAR cells ($P < 0.001$). More profound regression of HER-2-overexpressing tumors was found with squalamine plus Herceptin. In parallel studies, MCF-7/PAR and HER-2 tumors were harvested after 7 days treatment (Fig. 5) and prepared for IHC staining to detect blood vessels (23). On scoring tumor microvessel density, HER-2 tumors exhibited more angiogenic activity than parent cancers ($P < 0.001$). Squalamine alone elicited a reduction of vessel density for either PAR or HER-2 tumors ($P < 0.001$), and IHC analyses revealed a further reduction of angiogenesis in mice with MCF-7/HER-2 tumors treated with a combination of Herceptin with squalamine ($P < 0.01$) (data not shown).

Studies with 2C4 antibody to HER-2 receptors are underway. Preliminary findings suggest that 2C4 antibody (38,39), unlike Herceptin, has antitumor activity in both MCF-7 parent and HER2-overexpressing breast tumors. Combination of 2C4 and receptor tyrosine kinase inhibitors (40,41) with squalamine is also planned in the coming funding period.

AIM 3. *Investigation of the efficacy of squalamine administered by oral and intravenous routes in blocking *in vivo* growth and progression of human breast cancer xenografts in nude mice.*

Experiments to assess the potential oral bioactivity of squalamine have begun. MCF-7 breast tumor cells are being implanted subcutaneously in estrogen-primed nude mice by established methods. After tumors achieve a size of 50-100 mm³, mice will be treated with squalamine at 5, 20 or 50 mg/kg by oral gavage. Antitumor activity and post-treatment assays of tumor microvessel density and apoptosis are planned, as well as assessments of animal weight and any notable treatment-related physiologic or behavioral effects.

KEY RESEARCH ACCOMPLISHMENTS

- Significant growth inhibition was elicited by squalamine alone for both parental and HER-2-overexpressing human breast tumor xenografts *in vivo*.

- Immunohistochemical evaluation of tumors revealed decreased microvessel density and increased tumor cell apoptosis. Although HER-2-overexpressing tumors had more angiogenic and less apoptotic activity than parental cancers, growth of both tumor types appear to be similarly reduced by treatment with squalamine.
- In HER-2-overexpressing breast tumors, combination of squalamine with Herceptin antibody to HER-2 receptors provides a more profound antitumor effect.
- In *in vitro* studies, we find that squalamine does not directly affect proliferation of breast tumor cells. However, squalamine significantly blocks VEGF-induced activation of p42/p44 and p38 MAP kinases and cell proliferation in human vascular endothelial cells.
- Squalamine binds with specificity and significant affinity to caveolae domains isolated from human vascular endothelial cells. This membrane region is known to function as a signaling platform for the regulation of vascular endothelial cell growth.

REPORTABLE OUTCOMES

Presentations

1. Pietras, R.J. "Squalamine blocks tumor-associated angiogenesis in human breast cancers". Presented at Jonsson Cancer Center Seminar Series, UCLA (June, 2004).
2. Pietras, R.J. "Steroidal agents and tumor-associated angiogenesis". Presented at FASEB Summer Research Conference, Tucson, Arizona (August, 2004).

Publications

1. Pietras, RJ and Weinberg, O (2005). Antiangiogenic steroids in human cancer therapy. *Evidence-Based Complementary and Alternative Medicine* (submitted for publication).

Additional Research Opportunities

Dr. Pietras, the Principal Investigator, was the Chairman of a FASEB Summer Research Conference on "Steroid Hormone Receptors" that was held July 31-August 5, 2004 in Tucson, Arizona, and work derived from the funded research was discussed at the Conference (see presentations above).

No patents, development of cell lines, informatics or additional funding opportunities to be reported at this time.

PERSONNEL

Richard J. Pietras, PhD, MD, Principal Investigator
Diana Marquez, MD, Assistant Researcher
Olga Weinberg, BS, Research Assistant

CONCLUSIONS

This study is intended to evaluate the notion that treating both breast cancer cells and the tumor-associated vasculature may be more effective than treating breast cancer cells alone. Studies in the first year of this award show that the antiangiogenic steroid, squalamine, directly inhibits VEGF-induced growth of vascular endothelial cells and, thereby, elicits a potent antitumor effect. In addition, growth factor receptors, such as HER-2, in breast tumors enhance VEGF secretion, and therapies targeted to this signaling axis appear to elicit beneficial indirect effects on the process of angiogenesis. This project will continue to evaluate antitumor effects of squalamine alone and combined with other therapies targeted to tumor cell growth factor receptors,

such as Herceptin, 2C4 antibody and receptor tyrosine kinase inhibitors, and, thereby, test the potential value of direct and indirect blockade of angiogenesis as an antitumor strategy in breast cancer. In conclusion, research goals from the 'statement of work' have been achieved for year 01 of this project.

REFERENCES

1. McPherson K, C Steel and J Dixon (2000). Breast Cancer-epidemiology, risk factors and genetics. *Brit. Med. J.* 321 : 624-628.
2. Aaronson S (1991). Growth factors and cancer. *Science* 254 : 1146-1152.
3. Bange J, E Zwick and A Ullrich (2001). Molecular targets for breast cancer therapy and prevention. *Nature Med* 7 : 548-552.
4. Slamon DJ, GM Clark, S Wong et al. (1987). Human breast cancer : Correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*, 235 : 177-180.
5. Slamon DJ, W Godolphin, L Jones, J Holt, S Wong, D Keith, W Levin, S Stuart, J Udove, A Ullrich and M Press (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science*, 244 : 707-710.
6. Wright C, B Angus, S Nicholson et al. (1989). Expression of c-erbB-2 oncoprotein : a prognostic indicator in human breast cancer. *Cancer Res.* 49 : 2087-2094.
7. Joshi M., A Lee, M Loda, M Camus, C Pedersen, G Heatley and K Hughes (1996). Male breast cancer : An evaluation of prognostic factors contributing to a poorer outcome. *Cancer* 77 : 490-498.
8. Pietras RJ, BM Fendly, V Chazin, MD Pegram, SB Howell and DJ Slamon (1994). Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. *Oncogene* 9 : 1829-1838.
9. Pegram M, A Lipton, R Pietras, D Hayes, B Weber, J Baselga, D Tripathy, T Twadell, J Glaspy and D Slamon (1995). Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer. *Proc. Am. Soc. Clin. Oncol.* 14 : 106.
10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *New Engl J Med.* 344 : 783-792.
11. Ferrara N, J Winer, T Burton, A Rowland, M Siegel, H Phillips, T Terrell, G Keller and A Levinson (1993). Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese Hanster Ovary cells. *J. Clin. Invest.* 91 : 160-170.
12. D'Angelo G, I Struman, J Martial and R Weiner (1995). Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kd N-terminal fragment of prolactin. *Proc. Natl. Acad. Sci. USA* 92 : 6374-6378.
13. McLees A, A Graham, K Malarkey, G Gould and R Plevin (1995). Regulation of lysophosphatidic acid-stimulated tyrosine phosphorylation of mitogen-activated protein kinase by protein kinase C- and pertussis toxin-dependent pathways in the endothelial cell line Eahy 926. *Biochem. J.*, 307 : 743-748.
14. Akhter S, Nath SK, Tse CM, Williams J, Zasloff M and Donowitz M (1999). Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na⁺/H⁺ exchanger isoform NHE3. *Am. J. Physiol.* 276(1 Pt 1) : C136-C144.
15. Eckhardt, SG (1999). Angiogenesis inhibitors as cancer therapy. *Hospital Pract.* 1: 63-78.
16. Weidner N et al. (1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. *J. Natl. Cancer Inst.* 84 : 1875-1887.
17. Weidner N, Semple J, Welch, W and Folkman J (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. *New Engl. J. Med.* 324 : 1-8.
18. Petit A, Rak J, Hung M, Rockwell P, Goldstein N, Fendly B and Kerbel R (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. *Am. J. Pathol.* 151 : 1523-1530.

19. Pietras RJ, M Pegram, N Wongvipat, N Ferrara, M Sliwkowski and DJ Slamon (1994). Reversal of human breast cancer cell growth and angiogenesis on combined therapy with antibodies to HER-2 receptor and to vascular endothelial cell growth factor. SPORE Investigators Meeting 2 : 14-15.
20. Folkman J and Y Shing (1992). Angiogenesis. J. Biol. Chem. 267 : 10931-10934.
21. Sills AK Jr, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH et al. (1998). Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Research 58 : 2784-2792.
22. Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS and Buxton D (1998). Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res 18 : 2567-2573.
23. Li D, J Williams and RJ Pietras (2002). Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene 21 : 2805-2814.
24. Folkman J. and D Ingber (1992). Inhibition of angiogenesis. Sem. Cancer Biol. 3: 89-96.
25. Moore KS, S Wehrli, H Roder, M Rogers, JN Forrest, D McCrimmon and M Zasloff (1993). Squalamine: An aminosterol antibiotic from the shark. Proc. Natl. Acad. Sci. USA 90 : 1354-1358.
26. Williams JI (1999). "Squalamine-A New Angiostatic Steroid". In: *Antiangiogenic Agents* (Teicher, B.A., editor, Humana Press, Totowa, NJ).
27. Bhargava P, N Trocky, J Marshall, N Rizvi, W Dahut, J Williams, K Nelson, K Holroyd, MHawkins (1999). A phase I safety, tolerance and pharmacokinetic study of rising dose, rising duration continuous infusion of MSI-1256F (squalamine lactate) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol : 623.
28. Patnaik A, E Rowinsky, L Hammond, A Thurman, M Hidalgo, L Siu, J Moczygemba, J Williams, K Holroyd, K Nelson, D Von Hoff and S Eckhardt (1999). A phase I and pharmacokinetic study of the unique angiogenesis inhibitor, squalamine lactate (MSI-1256F). Proc. Am. Soc. Clin. Oncol. : 622.
29. Goldman C, J Kim, W-L Wong, V King, T Brock and G Gillespie (1993). Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells. Mol.Biol.Cell 4 : 121-133.
30. Morales D, K McGowen, D Grant, S Maheshwari, D Bhartiya, M Cid, H Kleinman and H Schnaper (1995). Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 91 : 755-763.
31. Rousseau S, F Houle, J Landry and J Huot (1997). P38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15: 2169-2177.
32. Gorrin-Rivas M, H Chen, D Marquez and RJ Pietras (2002). Squalamine blocks tumor-associated angiogenesis and promotes antitumor effects of Herceptin in HER-2/neu-overexpressing human breast cancer cells. Proc. Am. Assoc. Cancer Res. 43 : 521-522.
33. Yang S, Xin X, Zlot C, Ingle G, Fuh G, Li B, Moffat B, de Vos AM and Gerritsen ME (2001). Vascular endothelial cell growth factor-driven endothelial tube formation is mediated by vascular endothelial cell growth factor receptor-2, a kinase insert domain-containing receptor. Arterioscler Thromb Vasc Biol 21:1934-40.
34. Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J and Huot J (2000). Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem. 275 : 10661-10672.
35. Pietras RJ and CM Szego (1980). Partial purification and characterization of oestrogen receptors in subfractions of hepatocyte plasma membrane. Biochem. J. 191: 743-760.
36. Koleske AJ, Baltimore D, Lisanti MP (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci U S A 92 : 1381-1385.
37. Bickel P, Scherer P, Schnitzer J, Oh P, Lisanti M and Lodish H (1997). Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. J Biol Chem. 272 : 13793-13802.

38. Agus D, R Akita, W Fox, J Lofgren, B Higgins, K Maiese, H Scher and M Sliwkowski (2000). A potential role for activated HER-2 in prostate cancer. *Sem. Oncol.* 27 (Suppl 11): 76-83.
39. Lewis-Phillips GD, Totpal K, Kang K, Crocker L, Schwall R and Sliwkowski M (2002). In vitro and in vivo efficacy of a novel HER2 antibody, rhuMAB 2C4, on human breast and lung tumor cells. *Proc. Am. Assoc. Cancer Res.* 43 : 719.
40. de Bono J and Rowinsky E (2002). The erb B receptor family: A therapeutic target for cancer. *Trends in Molecular Med* 8 : S19-S26.
41. Akita RW, Dugger D, Phillips G, Lafleur M, Kang K, Erickson S, Romero M, Schwall R and Sliwkowski M (2002). Effects of the EGFR inhibitor TARCEVA on activated ErbB2. *Proc. Am. Assoc. Cancer Res.* 43 : 1003.